LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Risk for Colorectal Cancer Linked to Polyps and Adenomas

By LabMedica International staff writers
Posted on 25 Oct 2017
Print article
Image: The histologic appearance of serrated polyps: (A) normal colon mucosa; (B) sessile serrated adenoma with saw tooth appearance of the crypts in the longitudinal cut (Photo courtesy of Dr. Cuatrecasas).
Image: The histologic appearance of serrated polyps: (A) normal colon mucosa; (B) sessile serrated adenoma with saw tooth appearance of the crypts in the longitudinal cut (Photo courtesy of Dr. Cuatrecasas).
Most colorectal cancer develops from precursors known as polyps, the most common of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.

Another type of polyp known as serrated polyps may proceed up to 15% of colorectal cancer. Serrated polyps may occur in up to 20% of all adults over 50 years of age, however, when it comes to progression to colorectal cancer, less is known about serrated polyps than conventional adenomas.

Scientists at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) collected data from a population-based colonoscopy registry that has been collecting and analyzing data on colonoscopies across the state of New Hampshire since 2004, including rates of adenoma and serrated polyp detection. Patients completed a questionnaire to determine demographic characteristics, health history, and risk factors for colorectal cancer (CRC), and were followed from index colonoscopy through all subsequent surveillance colonoscopies. The analyses included 5,433 participants (median age 61 years; 49.7% male) with two colonoscopies (median time to surveillance, 4.9 years).

Each index risk group, were assessed for size and by histology. Two analyses were performed. The primary analysis compared 817 participants with high-risk adenoma (HRA) with or without synchronous serrated polyps (SP) and those 3,198 with no adenoma with or without synchronous serrated polyps at index colonoscopy. The secondary analysis included 1,418 participants with low risk adenoma (LRA) with and without synchronous serrated polyps and those 3,198 with no adenoma with and without serrated polyps at index colonoscopy.

The investigators found that HRA and synchronous large SP (odds ratio [OR] = 5.61), HRA with synchronous traditional serrated adenomas (STSA) (OR = 16.04), and HRA alone (OR = 3.86) at index colonoscopy significantly increased the risk of metachronous HRA compared to the reference group (no index adenomas or serrated polyps). Large index SPs alone (OR=14.34) or index STSA alone (OR = 9.70) significantly increased the risk of a large metachronous SP.

The authors concluded that in an analysis of data from a population-based colonoscopy registry, they found index large SP or index STSA with no index HRA increased risk of metachronous large SPs but not metachronous HRA. HRA and synchronous SPs at index colonoscopy significantly increased risk of metachronous HRA. Individuals with HRA and synchronous could therefore benefit from close surveillance.

Joseph C. Anderson, MD, the lead author of the study, said, “We found that while people with serrated polyps were at increased risk for future serrated polyps, they were not at risk for future high-risk adenomas. Not surprisingly, people with high-risk adenomas were at increased risk for high-risk adenomas. However, we made a novel observation that people with both serrated polyps and high-risk adenomas had a risk for future high-risk adenomas that was substantially higher than even people with high-risk adenomas alone.” The study was published on September 16, 2017, in the journal Gastroenterology.

Related Links:
Dartmouth-Hitchcock Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more